| Patient | Vincent van Gogh |
|---|---|
| Date of birth | 1990-03-30 |
| Identifiers | MRN HR-NI010-SYN; SSN (made up) 000-10-3198 |
| Document date | 2026-02-02 |
| Author | Elise Verhoeven, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Two-week review, seen the same day by psychiatry with the coordinated specialty care team. [S]
Mr. van Gogh returns two weeks after his first visit, four weeks after aripiprazole 10 mg was started in hospital, and is seen by Dr. Feld of the coordinated specialty care team on the same day. He has taken every dose. He has had no confusion and hears nothing by day, but on some nights he still hears his name called as he falls asleep, and on those nights he feels for a while that people in the street are talking about him; by morning he knows this is not so. He sleeps about six hours with breaks. His mood is a little better: he feels less ashamed and has started to sketch, but still cannot paint for long. The passive thoughts that it would be easier not to wake up come less often; he has had no thoughts of suicide or self-harm. He drinks two or three glasses of wine most evenings and no spirits since discharge. He has noticed no restlessness or stiffness. He had his brain MRI and EEG this morning, after a night of shortened sleep as instructed. [S]
| Element | Detail |
|---|---|
| Aripiprazole | 10 mg daily for four weeks, every dose taken |
| Psychotic symptoms | Hears his name called at sleep onset on some nights, with brief suspiciousness; none by day |
| Mood | Somewhat better; PHQ-9 11; item 9 scored 1, less often |
| Sleep | About six hours, broken |
| Alcohol | Two or three glasses of wine most evenings; no spirits |
| Side effects | None noticed |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever; appetite normal |
| Neurological | Negative | No restlessness, stiffness, tremor, seizures, or episodes of lost time |
| Ears, nose, mouth, and throat | Negative | Left ear wound healed; hearing unchanged |
| Psychiatric | Positive | Night-time perceptual disturbances at sleep onset; low mood improving; passive thoughts of not waking up less often; no suicidal intent or plan |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Aripiprazole 10 mg oral tablet, one tablet by mouth once daily (started in hospital) | One tablet by mouth once daily | Oral route | 2026-01-05 to 2026-02-02 | completed | S |
| Aripiprazole 15 mg oral tablet, one tablet by mouth once daily | One tablet by mouth once daily | Oral route | 2026-02-02 to 2026-02-16 | completed | S |
| Naltrexone 50 mg oral tablet, one tablet by mouth once daily | One tablet by mouth once daily | Oral route | 2026-02-02 | active | S |
| Thiamine 100 mg oral tablet, one tablet by mouth daily (started in hospital) | One tablet by mouth daily | Oral route | 2026-01-05 to 2026-07-20 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-02-02 | Body height | 170 | cm | S |
| 2026-02-02 | Body weight | 64.5 | kg | S |
| 2026-02-02 | Body mass index (BMI) [Ratio] | 22.3 | kg/m2 | S |
| 2026-02-02 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-02-02 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-02-02 | Heart rate | 82 | /min | S |
| 2026-02-02 | Respiratory rate | 14 | /min | S |
| 2026-02-02 | Body temperature | 36.6 | Cel | S |
| 2026-02-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-02-02 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 11 | {score} | S |
Vital signs recorded on 2026-02-02; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 64.5 kg; waist 86 cm; blood pressure 124/78, pulse 82 |
| Head and ears | Left ear wound healed, without infection |
| Neurological | No akathisia, rigidity, tremor, or abnormal movements; AIMS score 0 |
| Psychiatric | Quiet and cooperative; affect constricted but brighter; thought process organized; no hallucinations or delusions elicited today; insight good |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| First episode of psychosis with mood features: weeks of very little sleep, intense work and expansive plans, then acute confusion, hallucinations and suspiciousness with self-injury, and low mood since discharge. Diagnosis provisional; differential: bipolar I disorder with psychotic features, brief psychotic or schizophreniform disorder, alcohol withdrawal delirium or alcohol-induced psychotic disorder, and psychosis related to focal epilepsy. Synthetic modern episode linked to his documented first crisis | active | provisional | F29 | S — Synthetic modern coding of the documented first crisis. Unspecified psychosis is coded because the cause is not yet established; the retrospective diagnoses stay in the claims. |
| Alcohol use disorder, moderate (heavy daily wine and anise spirits before the episode); synthetic modern episode linked to his documented heavy drinking | active | confirmed | F10.20 | S — Synthetic modern coding of the documented drinking and its retrospective interpretation. |
| Self-injury to the left ear during the acute confusional episode, without suicidal intent; wound healed after surgical care in hospital | active | confirmed | Z91.52 | S — Synthetic modern coding of the documented injury; no detail of the injury is recorded. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Medication safety | Antipsychotic dose, adherence, and response | Every visit | Completed today | Aripiprazole 10 mg for four weeks with full adherence; partial response; increased to 15 mg |
| Survey | Psychotic and mood symptoms, and early warning signs | Every visit | Completed today | Name called at sleep onset on some nights; brief night-time suspiciousness; none by day |
| Examination | Akathisia, parkinsonism, and sedation | Every visit in the first months and after any dose change | Completed today | No akathisia, parkinsonism, or sedation |
| Examination | Abnormal Involuntary Movement Scale (AIMS) | Baseline, then every 6 months | Completed today | Baseline AIMS score 0, done with the consultation; repeat at six months |
| Examination | Weight and BMI | Every visit for 6 months after starting, then quarterly (CMID: baseline, 4, 8, and 12 weeks, then quarterly) | Completed today | 64.5 kg at four weeks, from 64.0 at intake |
| Examination | Waist circumference | Baseline, then yearly | Completed today | 86 cm. This baseline was due at intake and was taken today instead; nothing was lost because weight was measured at intake. Waist is now part of the visit template |
| Examination | Blood pressure | Baseline, 12 weeks, then yearly | Up to date | 128/80 at intake; 124/78 today |
| Laboratory | Fasting glucose and A1c | Baseline, 12 weeks to 4 months, then yearly | Up to date | Fasting glucose 91 mg/dL and A1c 5.3% at intake; next at 12 weeks |
| Laboratory | Fasting lipid panel | Baseline, 12 weeks to 4 months, then yearly | Up to date | Total cholesterol 184, LDL 106, HDL 52, triglycerides 130 mg/dL at intake; next at 12 weeks |
| Laboratory | Prolactin | If symptoms of high prolactin | Not indicated | Aripiprazole rarely raises prolactin; no symptoms |
| Laboratory | Electrocardiogram | Before starting if there are cardiac risk factors or QT-prolonging drugs | Not indicated | No cardiac history, fainting, or QT-prolonging drugs; aripiprazole has little effect on the QT interval |
| Laboratory | First-episode workup (MRI and EEG) | Once, in the first-episode workup | Completed today | Brain MRI and sleep-deprived EEG done this morning; results pending |
| Survey | Depression measure (PHQ-9) | Monthly during acute treatment, every 2 to 4 weeks in continuation, then periodically | Completed today | PHQ-9 11, from 13; item 9 scored 1 |
| Survey | Suicide-risk review, safety plan, lethal means, and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | Passive thoughts of not waking up less often, no intent or plan; safety plan reviewed; no firearm access; medicines two weeks at a time; the 988 Suicide & Crisis Lifeline in his phone |
| Self-management | Sleep | Every visit | Completed today | About six hours, broken; regular times and less evening coffee agreed |
| Survey | Drinking (AUDIT-C and PEth) | PEth at intake and at each check while drinking continues; AUDIT-C yearly | Up to date | AUDIT-C 9 and PEth 284 ng/mL at intake; two or three glasses most evenings now |
| Medication safety | Naltrexone: liver tests and opioid exposure | Liver tests before starting, then at 1 to 3 months and every 6 to 12 months | Completed today | AST 58, ALT 44 U/L at intake, well below three times the upper limit; urine drug test negative for opioids; naltrexone started |
| Medication safety | Thiamine | While drinking heavily | Completed today | Taking thiamine 100 mg daily since the hospital |
| Referral | Psychiatry consultation | At the start of treatment for a first episode | Completed today | Seen by Dr. Feld today |
| Self-management | Coordinated specialty care engagement | Ongoing, for up to two to three years | Completed today | Enrolled today; first meetings with the care coordinator and therapist booked |
Goal progress:
Guideline basis: The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia, Third Edition (2020); Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder (2018); Consensus development conference on antipsychotic drugs and obesity and diabetes (2004); Recovery After an Initial Schizophrenia Episode (RAISE): coordinated specialty care for first-episode psychosis (2026); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)
Follow-up: Six-week visit in four weeks with liver tests, PEth, the PHQ-9, and the MRI and EEG results. Care coordinator by phone weekly. Call at once for restlessness, voices by day, or dark thoughts. Next scheduled visit 2026-03-02: six-week review: symptoms, side effects, alcohol, sleep, and test results. [S]